In VivoThe biotechnology sector faces an unprecedented convergence of challenges that has fundamentally altered the industry landscape. Capital availability has contracted dramatically across all traditional
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare
ScripInsmed capitalized on the company’s better-than-expected Phase IIb clinical trial readout for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), which sent its s
ScripEli Lilly showed its confidence in Scorpion Therapeutics’ precision drug development efforts by agreeing in January to pay up to $2.5bn for the company to access its lead drug candidate, the PI3Kα i